

# The Reality of Vulnerable Plaque Detection and Clinical Implications

*Gary S. Mintz, MD*

**Cardiovascular Research Foundation  
New York, NY**



CARDIOVASCULAR RESEARCH  
FOUNDATION




COLUMBIA UNIVERSITY  
MEDICAL CENTER

Currently, the only technique  
that has prospectively linked  
lesion phenotype to late events  
is VH-IVUS




# VH-TCFA and Non Culprit Lesion Events in PROSPECT



Lesion HR	3.90 (2.25, 6.76)	6.55 (3.43, 12.51)	10.83 (5.55, 21.10)	11.05 (4.39, 27.82)
P value	<0.0001	<0.0001	<0.0001	<0.0001
Prevalence*	46.7%	15.9%	10.1%	4.2%

# Events versus number of factors

$PB_{MLA} \geq 70\%$ ,  $MLA \leq 4.0\text{mm}^2$ , and/or VH-TCFA



# VIVA: Virtual Histology in Vulnerable Atherosclerosis




- 932 non-culprit lesions in 170 pts were identified with 3-vessel IVUS imaging
- At a median follow-up of 625 days, there were 18 culprit and non-culprit MACE in 16 pts
  - 14 revascularizations, 2 MIs, and 2 deaths
- Univariate predictors of non-culprit MACE
  - Non-calcified VH-TCFA (p=0.025)
  - MLA <4mm<sup>2</sup> (p=0.021)
  - Plaque burden >70% (p<0.001)
  - Remodeling index (p=0.014)

# Optical Coherence Tomography

**Fibroatheroma**

**TCFA**

**Macrophage  
Accumulations**



CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER

White










Light Yellow



Yellow




Intense Yellow



# ROC Analysis of Validation of NIR Spectroscopy in 51 Autopsy Hearts (algorithm for detection of confluent [ $>0.2\text{mm}$ thick and $>60^\circ$ ] and relatively superficial necrotic core [overlying mean fibrous cap thickness $<0.45\text{mm}$ ])

Percent Positive Agreement




1-Percent Negative Agreement




# NIRS vs Histology

mm of  
pullback



high



low




# 314 calcified nodules in PROSPECT




- The prevalence of at least one calcified nodule was 16% per artery (250 of 1573) and 30% per patient (185 of 623).
- Two or more calcified nodules were detected in 48 coronary arteries (3%) in 76 patients (12%).
- The angiographic appearance was severe calcium in 3, moderate calcium in 35, hazy in 19, and normal in 257
- The VH-IVUS appearance was a fibroatheroma in 42% (116 of 276) , but only a VH-TCFA in 5.

# Longitudinal distribution of 314 calcified nodules




— **Calcified nodule cohort**  
 — **Non-calcified nodule cohort**



**Number at risk**

<b>CN cohort</b>	185	170	166	162	156	150	90
<b>Non-CN cohort</b>	438	389	370	352	338	324	190

# OCT Erosion




# How common are vulnerable plaques?



# Number of thin-cap fibroatheromas in patients dying with MI, sudden death, or noncardiac causes and studied at necropsy

Cross-sectional analysis




Longitudinal analysis

	All pts	Pts with $\geq 1$ ruptured plaque	Pts with $\geq 1$ TCFA or ruptured plaque	Pts with CV death
# of patients	50	14	20	33
# of ruptured plaques	19 (0.38/pt)		19 (0.95/pt)	15 (0.45/pt)
# fibroatheromas	193			
# TCFAs	23 (0.46/pt)	15 (1.21/pt)	23 (1.15/pt)	18 (0.55/pt)

# PROSPECT: Per patient incidence of VH-TCFAs

# lesions/pt per coronary tree: ■ 0 ■ 1 ■ 2 ■ 3 ■ ≥4






**Are all non-culprit events in the first year post-PCI related to vulnerable plaques? Or are some related to incomplete revascularization at the time of initial PCI?**





# Non-culprit lesion MACE (%)



### Number at risk

	0	1	2	3
NCL related, all	697	595	553	521
- without RLP	697	610	577	551
- with RLP	697	620	579	550




	Significant Progression	p	No Significant Progression
Time to events (median)	401	0.07	223
Baseline DS	27 ± 16%	<0.0001	49 ± 19%
Follow-up DS	72 ± 14%	0.0001	59 ± 16%
DS progression	44 ± 18%	<0.0001	5 ± 8%


# PROSPECT: Angiographic severity vs high risk morphology (n=3115)

	Quartile			
	1st	2nd	3rd	4th
QCA DS (%)	2.82 (2.56, 3.08)	9.95 (9.82, 10.08)	17.67 (17.47, 17.88)	33.52 (32.90, 34.14)
NC volume, %	12.3 (11.6, 13.0)	12.5 (11.8, 13.2)	13.0 (12.3, 13.7)	14.0 (13.3, 14.7)
VH-TCFA	13.4%	22.0%	24.4%	30.3%
FA	48.6%	56.2%	62.3%	72.3%

# of high risk morphologies

- Three
- Two
- One
- None





Number at risk

1 <sup>st</sup> quartile	778	726	717	693	680	655	416
2 <sup>nd</sup> quartile	779	721	711	692	679	659	411
3 <sup>rd</sup> quartile	779	707	693	675	652	630	379
4 <sup>th</sup> quartile	779	722	706	684	668	654	430




**Will imaging the proximal and mid segments of the three major epicardial vessels detect all vulnerable plaques?**



# Pathology spatial Distribution of Advanced Coronary Lesions




# Angiographic location of acute coronary occlusions



LAD

LCX

RCA



# PROSPECT: Completeness of 3-vessel IVUS and VH-IVUS imaging

Event type	Total # of events	Baseline QCA at event site	Baseline IVUS at event site	Baseline VH at event site
All MACE	245	227	140	132
Culprit lesion related	120	120	84	76
<b>Non culprit lesion related</b>	<b>107</b>	<b>107</b>	<b>56</b>	<b>56</b>
- With RLP	51	51	31	31
- Without RLP	56	56	25	25
Indeterminate	18	0	0	0





# Location of MACE Events

	All (n=228)	Culprit lesion related (n=121)	Non culprit lesion related (n=107)
LM	4 (1.8%)	1 (0.8%)	3 (2.8%)
LAD	82 (36.0%)	48 (39.7%)	34 (31.8%)
LCX	63 (27.6%)	30 (24.8%)	33 (30.8%)
RCA	79 (34.6%)	42 (34.7%)	37 (34.6%)
Proximal vessel	69 (30.3%)	43 (35.5%)	26 (24.3%)
Mid vessel	51 (22.4%)	30 (24.8%)	21 (19.6%)
Distal vessel	35 (15.4%)	18 (14.9%)	17 (15.9%)
Branch*	73 (32.0%)	30 (24.8%)	43 (40.2%)

*Excludes indeterminate lesions. Includes, diagonal, ramus, obtuse marginal, R/L PDA, R/L PLAS.*



# Is three vessel invasive imaging safe?



CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER

# Complications attributed to the 3-vessel IVUS imaging procedure (n=697, non-hierarchical)

Death	0 (0%)
MI	3 (0.4%)
- Q-wave (from dissection)	1
- non Q-wave (from dissection)	2
PCI or CABG	10 (1.4%)
- CABG (from perforation)	1
- CABG (from dissection)	2
- PCI (from dissection)	9
<b>Any imaging complication*</b>	<b>11 (1.6%)</b>

\*Some pts had more than one complication

Safety becomes an even more important concern if imaging must be repeated periodically.













# Change in non-culprit lesion phenotype in 106 patients (201 lesions) with plaque burden >40% from the Global VH Registry with baseline and 8-month follow-up VH analysis







- 75% of TCFAs healed and 25% remained unchanged although the location of the necrotic core in contact with the lumen shifted axially.
- Compared to TCFAs that healed, TCFAs that did not change were more proximal in location and had larger lumen area, vessel area, plaque area, calcium area, and necrotic core area.
- 12 new TCFAs were noted: 6 were PIT and 6 were ThFA at baseline.
- No fibrotic or fibrocalcific plaque evolved into a TCFA.

# Baseline

## Follow-up

		PIT (n=48)	TCFA (n=17)	ThCFA (n=109)	Fibrotic (n=23)	Fibrocalcific (n=20)
						
PIT (n=62)		44	6	12	0	0
TCFA (n=20)		0	5	14	2	0
ThCFA (n=93)		0	6	83	3	1
Fibrotic (n=22)		4	0	0	18	0
Fibrocalcific (n=19)		0	0	0	0	19

# Change in non-culprit lesion phenotype in 100 pts (100 lesions: plaque burden >40%) from HORIZONS: Baseline and 13-month follow-up VH-IVUS


		<i>Follow-up</i>			
		PIT (n=11)	TCFA (n=54)	ThCFA (n=32)	
<i>Baseline</i>					
	PIT (n=16)		6	3	7
	TCFA (n=43)		2	33	8
	ThCFA (n=40)		1	19	20

# Baseline


TCFA




TCFA




TCFA




PIT




ThCFA



Fibrotic



TCFA



TCFA



Follow-up



# And some vulnerable plaques rupture asymptotically and are detected incidentally while others heal and contribute disease progression

- *Maehara et al. J Am Coll Cardiol 2002;40:904-10*
- *Rioufol et al. Circulation. 2002;106:804-8*
- *Hong et al. Circulation 2004;110:928-33*
- *Fuji et al. Circulation 2003;108:2473-8*
- *Burke et al. Circulation 2001;103:934-40*
- *Rioufol et al. Circulation 2004;110:2875-80*
- *Hong et al. Atherosclerosis. 2007;19:107-14*



How common are major  
vulnerable plaque events  
(death/MI) in 2012, really?



# PROSPECT: 3-year follow-up hierarchical MACE assuming indeterminate events (ie., death) are non-culprit lesion related

	All	Culprit lesion related	Non culprit lesion related
Cardiac death	1.9% (12)	0.2% (1)	1.8% (11)
Cardiac arrest	0.3% (2)	0.3% (2)	0% (0)
MI (STEMI or NSTEMI)	2.7% (17)	1.7% (11)	1.2% (7)
Rehospitalization for unstable or progressive angina	15.4% (101)	10.4% (69)	10.5% (67)
Composite MACE	20.4% (132)	12.9% (83)	13.3% (85)
<b>Cardiac death, arrest or MI*</b>	<b>4.9% (31)</b>	<b>2.2% (14)</b>	<b>2.9% (18)</b>

\*In patients post-PCI for STEMI/NSTEMI and treated with optimal medical therapy and followed as part of a clinical study

# VIVA: Virtual Histology in Vulnerable Atherosclerosis

- 932 non-culprit lesions in 170 pts were identified with 3-vessel IVUS imaging
- At a median follow-up of 625 days, there were 18 culprit and non-culprit MACE in 16 pts
  - 14 revascularizations, 2 MIs, and 2 deaths




# Who should we study? Primary prevention versus secondary prevention?



# PROSPECT: Independent predictors of patient level events

	Hazard ratio	P value
Insulin dependent diabetes mellitus	3.32	0.005
Prior PCI	2.03	0.02

Variables entered into the model: age, gender, hypertension, insulin dependent diabetes, prior PCI, CRP at baseline, family history



# Conclusion

- We can now say with confidence that we are able to detect TCFAs.
- However, that does not mean that searching for a vulnerable plaque in patients will ever make clinical sense unless we can identify a truly high risk patient population or one that does not respond to conventional medical therapy in order to justify invasive imaging – especially, since we do not have a focal therapy to offer.

Reference: Vancraeynest et al. Imaging the vulnerable plaque. J Am Coll Cardiol 2011;57:1961-79

